Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A neuropeptide that acts as the master regulator of the reproductive hormone axis. Kisspeptin neurons in the hypothalamus control the release of GnRH (gonadotropin-releasing hormone), which in turn drives LH and FSH production. Increasingly studied for fertility treatment, hypogonadism, and as a diagnostic tool for reproductive disorders. Also being explored for its role in emotional and sexual brain processing.
A synthetic analog of alpha-MSH that acts on melanocortin receptors. Originally developed at the University of Arizona as a potential tanning agent, it gained notoriety for potent sexual arousal and appetite suppression effects.
Binds to the KISS1R (GPR54) receptor on GnRH neurons in the hypothalamus, triggering GnRH release. This stimulates the anterior pituitary to release LH and FSH, which drive testosterone production in males and ovulation in females. Kisspeptin is the upstream 'gatekeeper' of the entire HPG axis.
Activates MC1R (melanocortin 1 receptor) to stimulate melanin production. Also activates MC3R and MC4R, which mediate sexual arousal, appetite suppression, and cardiovascular effects. The MC4R activation is primarily responsible for its erectile and libido-enhancing properties.
- Fertility treatment (investigational)
- Hypogonadism evaluation
- IVF protocols (as GnRH trigger alternative)
- Reproductive endocrinology research
- Libido and sexual function research
- Skin tanning
- Sexual dysfunction treatment
- Libido enhancement
- Erectile dysfunction (investigational)
- Injection site discomfort
- Headache and flushing
- Potential for ovarian hyperstimulation in women
- Short half-life requires frequent dosing or infusion
- Limited long-term safety data
- Nausea and vomiting (common)
- Facial flushing
- Spontaneous and prolonged erections
- Melanocyte stimulation may activate existing moles or nevi
- Potential cardiovascular effects
- High abuse potential from gray market
- Very limited controlled clinical trial data
Not FDA-approved. Active clinical trials at Imperial College London and other institutions for fertility applications. Being studied as a safer alternative to hCG triggers in IVF (lower risk of ovarian hyperstimulation syndrome). No US-approved formulation exists.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review before February 2027. One of the more controversial compounds on the list due to its widespread gray-market use and safety concerns. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: By February 2027
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.